Health Care [ 7/12 ] | Biotechnology [ 39/74 ]
NASDAQ | Common Stock
Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors.
The company is conducting a Phase 2 clinical trial in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1.
This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy).
The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.
The company is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | -0.10 Increased by +96.84% | -0.25 Increased by +60.00% |
| Aug 9, 24 | -0.20 Decreased by -6.15 K% | -0.19 Decreased by -5.26% |
| May 10, 24 | -0.18 Decreased by -3.17 K% | -0.16 Decreased by -12.50% |
| Mar 22, 24 | -0.63 Decreased by -6.20 K% | -0.38 Decreased by -65.79% |
| Nov 13, 23 | -3.17 Decreased by -31.55 K% | - |
| Aug 7, 23 | -0.00 Increased by +68.00% | - |
| May 31, 23 | -0.01 Increased by +45.00% | - |
| Mar 1, 23 | -0.01 Increased by 0.00% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -3.90 M Increased by +84.37% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -7.90 M Decreased by -153.99% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -5.02 M Increased by +2.86% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 191.76 K Increased by +N/A% | -4.42 M Increased by +55.32% | Decreased by -2.30 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -24.95 M Decreased by -697.68% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -3.11 M Increased by +9.00% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -5.17 M Decreased by -69.79% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -9.89 M Decreased by -293.65% | Decreased by N/A% Decreased by N/A% |